This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

2 December 2021, Virtual Conference
Delivered Live (CET) & On Demand Afterwards

James Killick
Partner at White & Case

Profile

James Killick is currently Head of White & Case’s EMEA Competition and Trade practice, and previously led the Firm's Global Pharmaceuticals and Healthcare practice from 2010-2014. He is a litigator with a broad range of European law experience, advising clients on pharmaceuticals, competition, and international trade (customs, export control, dumping).

He regularly advises leading pharmaceutical multinationals and the major US and EU industry pharmaceutical associations on EU and national law and policy affecting the pharmaceuticals sector. His pharmaceutical practice covers competition law, including licensing and distribution issues, regulatory matters, intellectual property, data protection, and national implementation of EU measures, notably on pricing and reimbursement.

He has been involved in pleading a number of leading cases in the European Courts, including Servier (patent settlement agreements), Pfizer/Flynn (excessive pricing), Microsoft v Commission (compulsory licensing; treatment of trade secrets), Hanner (Swedish retail monopoly on pharmaceuticals), Pfizer v Council (precautionary principle), IMS Health (compulsory licensing), and Servier v Commission (banning of pharmaceuticals). He was also actively involved in the European Commission's pharmaceutical sector inquiry, representing a major global company, and has spoken extensively on this topic.

James is widely recognised in the market and speaks and publishes extensively. He is ranked in Chambers Global 2021 for Life Sciences and Competition/European Law; EU Regulatory - Pharma, Medical Devices and Biotech; and Customs, Trade, WTO and Anti-Dumping.

Agenda Sessions

  • Recent Developments in Patents including Patent Pooling, Copaxone Investigation & Reverse Patent Settlements

    15:45